CD14+ CD163+ IL-10+ monocytes/macrophages: Pro-angiogenic and non pro-inflammatory isolation, enrichment and long-term secretion profile.
The establishment of a stable endothelial layer on a biomaterial suture is a well known strategy to achieve hemocompatibility. The endothelialisation is supported by factors as e.g. vascular endothelial growth factor (VEGF), which can be secreted by monocytes/macrophages (mo/mΦ) in an angiogenic milieu. In order to avoid detrimental inflammation triggered by these mo/mΦ, we established a protocol for the generation of alternatively activated macrophages and studied their response towards VEGF-A165. We could generate sufficient amounts of these CD14+ CD163+ IL-10+ mo/mΦ from buffy coats(8.6 ± 4.7 × 105 cells/mlbuffy coat). Furthermore, we achieved a VEGF-A165 secretion in the nanogram range. The VEGF-A165 secretion increased 2.1-fold within 14 days from 7.6 ± 2.2 to 16.1 ± 2.5ng/ml when the cells were grown with a VEGF-A165 supplemented (10ng/ml) cell culture medium. Within this time period the secretion levels of other pro-angiogenic growth factors (bFGF, PDGF-BB) and immunomodulatory cytokines (IL-10, IL-12, IL-1ra, TNFα, IFNγ) reached only the picogram range. These results suggest that angiogenically stimulated CD14+ CD163+ IL-10+ mo/mΦ might be useful as a cellular cytokine delivery system supporting endothelialisation of biomaterials without inducing pro-inflammatory effects.
Centre for Biomaterial Development, Institute for Polymer Research, GKSS Research Centre Geesthacht GmbH, Teltow, Germany.
A
A
Mayer
S
S
Lee
F
F
Jung
G
G
Grütz
A
A
Lendlein
B
B
Hiebl
D043925:Angiogenesis Inducing Agents / Q000276:immunology / Q000494:pharmacology*; D015703:Antigens, CD / Q000276:immunology*; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology*; D002469:Cell Separation; D002478:Cells, Cultured; D006801:Humans; D016753:Interleukin-10 / Q000276:immunology*; D018950:Lipopolysaccharide Receptors / Q000276:immunology*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology*; D009000:Monocytes / Q000187:drug effects / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000276:immunology*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000494:pharmacology*; D000098902:CD163 Antigen
D043925:Angiogenesis Inducing Agents; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000098902:CD163 Antigen; D018950:Lipopolysaccharide Receptors; D010446:Peptide Fragments; D011956:Receptors, Cell Surface; D042461:Vascular Endothelial Growth Factor A; C511613:vascular endothelial growth factor A (138-165); D016753:Interleukin-10